The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...

More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, ...

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...

The global Liquid Biopsy Market is experiencing significant growth, driven by increasing cancer prevalence, advancements in ...